Theratechnologies Inc (TSE:TH)’s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$3.83 and last traded at C$3.85, with a volume of 92400 shares. The stock had previously closed at C$3.96.
A number of equities analysts have commented on the stock. Royal Bank of Canada cut their price objective on shares of Theratechnologies from C$7.00 to C$6.00 and set a “sector perform” rating on the stock in a report on Wednesday, October 9th. National Bank Financial decreased their price objective on shares of Theratechnologies from C$8.25 to C$7.00 and set a “sector perform” rating for the company in a research report on Wednesday, October 9th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of C$8.75.
The business has a fifty day moving average of C$4.66 and a 200 day moving average of C$5.57. The company has a debt-to-equity ratio of 167.71, a current ratio of 2.51 and a quick ratio of 1.94. The stock has a market cap of $304.73 million and a PE ratio of -42.02.
Theratechnologies (TSE:TH) last posted its quarterly earnings data on Tuesday, October 8th. The company reported C($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of C($0.04) by C$0.01. The business had revenue of C$21.30 million for the quarter, compared to analysts’ expectations of C$23.97 million. On average, equities research analysts expect that Theratechnologies Inc will post 0.07 EPS for the current year.
In related news, Director Dale Weil acquired 10,500 shares of Theratechnologies stock in a transaction on Tuesday, October 15th. The shares were purchased at an average cost of C$4.84 per share, for a total transaction of C$50,866.20. Following the purchase, the director now directly owns 10,500 shares of the company’s stock, valued at approximately C$50,866.20.
Theratechnologies Company Profile (TSE:TH)
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.